Table 5.
PD1/PD-L1 antibody-NK cell combination treatment in advanced or metastatic TNBC.
| NCT Number | Other IDs | Intervention | Trial status | Ref |
|---|---|---|---|---|
| NCT04551885 | FT516-102 | Avelumab + FT-516 | Recruiting | |
| NCT03387085 | QUILT-3.067 | Avelumab + haNK + IL-15 + vaccine + chemoradiation | Active ORR 67% PFS (13.7 mths) |
(156) |
FT-516, iPSC-derived NK cells with hnCD16; IL-15, interleukin 15; NK, natural killer cell; ORR, overall response rate; PFS, progression free survival.